| 1108P Real world (RW) sequencing outcomes with immunotherapy and targeted therapy (TT) in BRAF+ metastatic melanoma (The NOBLE study series) AB Warner, AA Tarhini, M Johnson, B Kang, A Nakasato, M Vance, ... Annals of Oncology 31, S748-S749, 2020 | 1 | 2020 |
| 1111P Suboptimal real-world (RW) outcomes for BRAF+ metastatic melanoma (MM) patients in 2L therapy (The NOBLE study series) AA Tarhini, AB Warner, M Johnson, B Kang, A Nakasato, M Vance, ... Annals of Oncology 31, S750, 2020 | | 2020 |
| 187TiP Phase II, multicenter study of autologous tumor infiltrating lymphocytes (TIL, LN 144/LN-145/LN-145-S1) in patients with solid tumours S Gettinger, H Kluger, A Schoenfeld, AB Warner, K He, A Sukari, ... Journal of Thoracic Oncology 16 (4), S799-S800, 2021 | 4 | 2021 |
| 622 Immune phenotype and iFRET functional analysis are biomarkers of response to neoadjuvant intralesional therapy for high risk stage II melanoma A Kirane, MC Lowe, MU Ahmad, S Sharma, M Serasanambati, AB Warner, ... Journal for ImmunoTherapy of Cancer 11 (Suppl 1), 2023 | | 2023 |
| 783 Trial in progress: a phase 1/2 open-label study (IOV-GM1–201) of TALEN-mediated PD-1–inactivated autologous tumor-infiltrating lymphocytes (TIL; IOV-4001) in patients with … A Betof, T Wise-Draper, K He, A Sarnaik, J Thompson, F Finckenstein, ... Journal for ImmunoTherapy of Cancer 10 (Suppl 2), 2022 | | 2022 |
| 789 Immune checkpoint blockade augments cyclophosphamide induced anti-tumor immunity by expanding effector CD8+ T cell clones in a preclinical melanoma model MM George, L Hamadene, NJ Ceglia, Y Marouf, D Hirschhorn, ... Journal for ImmunoTherapy of Cancer 11 (Suppl 1), 2023 | | 2023 |
| 790 Phase I clinical trial on intratumoral administration of autologous CD1c (BDCA-1)+/CD141 (BDCA-3)+ myeloid dendritic cells plus ipilimumab and AS01B in combination with … J Tijtgat, JK Schwarze, AS Vander Mijnsbrugge, S Raeymaeckers, ... Journal for ImmunoTherapy of Cancer 10 (Suppl 2), 2022 | 1 | 2022 |
| 878 T cell immunotherapies recruit and activate neutrophils to eliminate tumor antigen escape variants D Hirschhorn, S Budhu, L Kraehenbuehl, M Gigoux, D Schröder, A Chow, ... Journal for ImmunoTherapy of Cancer 11 (Suppl 1), 2023 | | 2023 |
| 883TiP A phase I/II open-label study (IOV-GM1-201) of TALEN-mediated PD-1 inactivated autologous tumor-infiltrating lymphocytes (TIL; IOV-4001) in patients with advanced … J Chesney, T Wise-Draper, AA Sarnaik, FG Finckenstein, P Hari, ... Annals of Oncology 33, S952, 2022 | 4 | 2022 |
| 96P Long-term outcomes after initial disease progression with anti-PD-1 in melanoma K Loo, BC Park, H Kalvin, K Panageas, D Johnson, AB Warner Immuno-Oncology and Technology 16, 2022 | | 2022 |
| A Phase 1/2 Open-Label Study (IOV-GM1-201) of TALEN®-Mediated PD-1 Inactivated Autologous Tumor-Infiltrating Lymphocytes (TIL; IOV-4001) in Patients With Advanced Melanoma and … J Chesney, T Wise-Draper, A Sarnaik, FG Finckenstein, P Hari, M Jagasia, ... | | |
| A phase 1/2 study to investigate the safety and efficacy of OBX-115 engineered tumor-infiltrating lymphocyte (TIL) cell therapy in patients (pts) with advanced solid tumors. AJ Schoenfeld, A Betof Warner, JA Chesney, SS Thomas, O Hamid, GK In, ... Journal of Clinical Oncology 42 (16_suppl), TPS9599-TPS9599, 2024 | | 2024 |
| A Phase 2, multicenter study of autologous tumor infiltrating lymphocytes (TIL, LN 144/LN-145/LN-145-S1) in patients with solid tumors. S Gettinger, H Kluger, A Schoenfeld, A Betof-Warner, K He, A Sukari, ... CANCER RESEARCH 81 (13), 2021 | | 2021 |
| A phase I/II study of neoadjuvant liposomal doxorubicin, paclitaxel, and hyperthermia in locally advanced breast cancer Z Vujaskovic, DW Kim, E Jones, L Lan, L McCall, MW Dewhirst, ... International Journal of Hyperthermia 26 (5), 514-521, 2010 | 102 | 2010 |
| A phase II study to evaluate the need for> two doses of nivolumab+ ipilimumab combination (combo) immunotherapy. MA Postow, DA Goldman, AN Shoushtari, AB Warner, MK Callahan, ... Journal of Clinical Oncology 38 (15_suppl), 10003-10003, 2020 | 21 | 2020 |
| A pilot trial of autologous tumor infiltrating lymphocytes (lifileucel, LN-144) for patients with asymptomatic melanoma brain metastases. A Betof Warner, JW Smithy, MA Postow, K Panageas, AJ Schoenfeld, ... Journal of Clinical Oncology 42 (16_suppl), TPS9603-TPS9603, 2024 | | 2024 |
| A pilot trial of autologous tumor infiltrating lymphocytes (lifileucel, LN-144) for patients with asymptomatic melanoma brain metastases. A Betof Warner, MA Postow, K Panageas, JW Smithy, AJ Schoenfeld, ... Journal of Clinical Oncology 41 (16_suppl), TPS9606-TPS9606, 2023 | 1 | 2023 |
| Abstract CT235: A Phase 2, multicenter study of autologous tumor infiltrating lymphocytes (TIL, LN 144/LN-145/LN-145-S1) in patients with solid tumors S Gettinger, H Kluger, A Schoenfeld, A Betof-Warner, K He, A Sukari, ... Cancer Research 81 (13_Supplement), CT235-CT235, 2021 | | 2021 |
| Abstract CT285: Trial in progress: A phase 1/2 study to investigate the safety and efficacy of OBX-115 engineered tumor-infiltrating lymphocyte (TIL) cell therapy in patients … SS Thomas, JA Chesney, O Hamid, GK In, AN Shoushtari, Y Samhouri, ... Cancer Research 84 (7_Supplement), CT285-CT285, 2024 | | 2024 |
| Adaptive dosing of nivolumab+ ipilimumab immunotherapy based upon early, interim radiographic assessment in advanced melanoma (the ADAPT-IT study) MA Postow, DA Goldman, AN Shoushtari, A Betof Warner, MK Callahan, ... Journal of Clinical Oncology 40 (10), 1059-1067, 2022 | 45 | 2022 |
Alexander N. ShoushtariAssistant Attending Physician, Memorial Sloan Kettering Cancer CenterVerified email at mskcc.org